Pharma-Bio Serv (PBSV) director awarded 20,000 stock options at $0.54

Rhea-AI Filing Summary

Pharma-Bio Serv, Inc. director Irving L. Wiesen reported a new stock option grant on a Form 4. On January 10, 2026, he received a stock option for 20,000 shares of Pharma-Bio Serv common stock. The option has an exercise price of $0.54 per share and an expiration date of January 10, 2031.

According to the filing, the option vests in two equal installments on July 10, 2026 and July 10, 2027. After this grant, Wiesen beneficially owns 20,000 derivative securities related to these options, held in direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WIESEN IRVING L

(Last) (First) (Middle)

315 W. 70TH STREET

APT. 3B

(Street)

NEW YORK NY 10023

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pharma-Bio Serv, Inc. [ PBSV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.54	01/10/2026		A		20,000		(1)	01/10/2031	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. The option vests in two equal installments on July 10, 2026 and July 10, 2027.

	/s/ Irving L Wiesen	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Irving L. Wiesen report in this Pharma-Bio Serv (PBSV) Form 4?

Irving L. Wiesen, a director of Pharma-Bio Serv, Inc., reported the grant of a stock option covering 20,000 shares of the company’s common stock on January 10, 2026.

How many stock options were granted to the Pharma-Bio Serv (PBSV) director and at what price?

The director received a stock option for 20,000 shares of Pharma-Bio Serv common stock with an exercise price of $0.54 per share.

What is the vesting schedule of Irving L. Wiesen’s Pharma-Bio Serv (PBSV) stock options?

The filing states that the option vests in two equal installments on July 10, 2026 and July 10, 2027, as noted in the footnote.

When do the reported Pharma-Bio Serv (PBSV) stock options expire?

The stock option granted on January 10, 2026 has an expiration date of January 10, 2031, after which it can no longer be exercised.

How many derivative securities does Irving L. Wiesen beneficially own after this Pharma-Bio Serv (PBSV) transaction?

Following the reported transaction, Irving L. Wiesen beneficially owns 20,000 derivative securities related to this stock option grant.

Is Irving L. Wiesen’s ownership in the Pharma-Bio Serv (PBSV) options direct or indirect?

The Form 4 identifies the ownership of the 20,000 stock options as direct (D), with no indirect ownership relationship disclosed.

What underlying security is associated with the reported Pharma-Bio Serv (PBSV) stock options?

The derivative security is a stock option, and the underlying security is Pharma-Bio Serv, Inc. common stock, with 20,000 shares underlying the option.